Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
Gilberto
G
de Lima Lopes
Stefan
S
Gluck
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007558:Italy; D008495:Medical Oncology / Q000191:economics*; D010506:Periodicals as Topic; D019057:Quality-Adjusted Life Years; D000068878:Trastuzumab; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab